Status:
COMPLETED
Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Stage I-III Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Our group has shown that increasing the radiation dose to pre-specified normal tissue dose constraints could lead to increased TCP with the same NTCP in patients with non-concurrent and concurrent che...
Detailed Description
Eligible patients (see below) will receive radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to an MLD (Mean Lung Dose) of 20 +/-1Gy, irrespective of lung function. ...
Eligibility Criteria
Inclusion
- Histological or cytological proven NSCLC
- IUCC stage I-III, or solitary metastases (\<6), which are amendable for radical local treatment.
- Performance status 0-2
- IMRT technique
Exclusion
- Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)
- Stage IV, except for solitary (\<6) metastases
- Performance status 3 or more
- No IMRT technique
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01166204
Start Date
May 1 2009
End Date
May 1 2017
Last Update
May 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAASTRO clinic
Maastricht, Limburg, Netherlands, 6229 ET